ArchiveJanuary 2017

Not so Silent Lesions. Will the Real Progressive MS stand Up.

Wundes A, Bowen JD, Kraft GH, Maravilla KR, McLaughlin B, von Geldern G, Georges G, Nash RA, Lu JQ. Brain pathology of a patient 7 years after autologous hematopoietic stem cell transplantation for multiple sclerosis. J Neurol Sci. 2017 ;373:339-341.  Aggressive immunosuppression followed by autologous hematopoietic stem cell transplantation (aHSCT) can be an effective...

The silent MS lesions

Exp Ther Med. 2017 Jan;13(1):91-96. doi: 10.3892/etm.2016.3950. Epub 2016 Dec 2. Magnetic resonance diffusion tensor imaging for occult lesion detection in multiple sclerosis. Chen J, Zhou C, Zhu L, Yan X, Wang Y, Chen X, Fang S. Abstract It remains challenging to locate occult lesions in patients with multiple sclerosis (MS). Diffusion tensor imaging (DTI) has been demonstrated to have the...

#ResearchSpeak: asymptomatic MS in siblings of MSers

How common is asymptomatic MS in siblings of MSers? #ResearchSpeak #MSBlog The study below confirms that siblings of people with MS have a high incidence of sub-clinical, or asymptomatic, MS. Almost 1 in 10 siblings of pwMS have MRI features of MS. This confirms the findings of an earlier Sardinian study and other studies demonstrating that siblings of pwMS have early markers of MS. The NIH study...

Rebound? What causes the emergence of disease after alemtuzumab

#MS Research #Clinical Speak There was a report of severe disease activity that occured within 6 months of the first infusion of alemtuzumab.This responded to B cell depletion. The first suggestion was this could be a novel CNS autoimmunity, as could occur as discussed by Profg yesterday However could it be disease reactivation? This created some contradicting ideas (see post and comments) from...

#ClinicSpeak & #NeuroSpeak: not everything that looks like MS is MS

How sure are you that you have MS? #ClinicSpeak #NeuroSpeak #MSBlog Not everything that looks like MS is MS. Did you know that about 1 person in 20 with MS does not have the disease? This won’t come as a surprise to you if you are a regular reader of this blog; I have posted on this issue several times in the past. Today’s post by the MouseDoctor on two patients...

Worsening after alemtuzumab

#MSresearch #Clinicspeak Haghikia A, Dendrou CA, Schneider R, Grüter T, Postert T, Matzke M, Stephanik H, Fugger L, Gold R. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol. 2017;16: 104-106. We have recently had reports suggesting that people taking alemtuzumab after fingolimod may be at increased risk of treatment failure. Bad news for alemtuzumab In...

#ThinkSpeak: unrelated comments as a forum for change

The best way to treat your pet troll is to be kind and patient; at Barts-MS we like to think that we are both kind and patient. #ThinkSpeak Do you use, and read, unrelated comments? This is a useful feature of our blog that we added many years ago to improve our offering. It is important to let the blog evolve over time, which explains why we have expanded our readership over the years. The idea...

All Antibodies are the same- think again!

New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.Robak T, Robak E. BioDrugs. 2011;25:13-25. Over the last few years, new generations of anti-CD20 monoclonal antibodies (mAbs) have been developed for potential benefits over the classical, first-generation mAb rituximab. Compared with rituximab, new mAbs have enhanced antitumor activity resulting from increased...

The Dre Approach to treating RR MS

Sawad AB, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis. J Comp Eff Res. 2017 . doi: 10.2217/cer-2016-0056. [Epub ahead of print] AIM:To compare the cost-effectiveness of different disease-modifying therapies’ strategies for treatment of relapsing-remitting multiple sclerosis...

Translate

Categories

Recent Posts

Recent Comments

Archives